X0306 4 2019-10-07 0001781983 Aprea Therapeutics, Inc. APRE 0001219014 ROCKLAGE SCOTT M 535 BOYLSTON STREET BOSTON MA 02116 true Common Stock 2019-10-07 4 C 0 1913910 A 1926073 I See footnotes Common Stock 2019-10-07 4 C 0 79746 A 80253 I See footnotes Common Stock 2019-10-07 4 C 0 492475 A 2418548 I See footnotes Common Stock 2019-10-07 4 C 0 20519 A 100772 I See footnotes Series B Convertible Preferred Stock 2019-10-07 4 C 0 1913910 D Common Stock 1913910 0 I See footnotes Series B Convertible Preferred Stock 2019-10-07 4 C 0 79746 D Common Stock 79746 0 I See footnotes Series C Convertible Preferred Stock 2019-10-07 4 C 0 492475 D Common Stock 492475 0 I See footnotes Series C Convertible Preferred Stock 2019-10-07 4 C 0 20519 D Common Stock 20519 0 I See footnotes These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Common Stock"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date. Shares are held directly by 5AM Ventures IV, L.P. Shares are held directly by 5AM Co-Investors IV, L.P. 5AM Partners IV, LLC is the sole general partner of each of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (collectively, the "5AM Funds"). The reporting person is a managing member of 5AM Partners IV, LLC and may be deemed to have shared voting and investment power over the shares beneficially owned by the 5AM Funds. The reporting person disclaims beneficial ownership of the shares of Common Stock and Preferred Stock held directly by the 5AM Funds, except to the extent of his pecuniary interest therein. /s/ Scott M. Coiante, attorney-in-fact 2019-10-07